The primary objective of this study is to observe safety and tolerability of Xeloda as used in medical practice, alone and in combination with docetaxel.

Inclusion Criteria:

Metastatic Breast Cancer:

• women >=18 years of age
• Patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
• Previous therapy should have included an anthracycline.
• Patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
• Female patients with histopathologically proven metastatic breast cancer
• Adequate bone marrow, liver, renal and cardiac functions

Colon Cancer:

• Patients >18 years of age
• Patients with histologicaly confirmed colon cancer
• Patients with potential curative tumor resection within 8 weeks before enrolment in the study
• Patients previously not treated with chemiotherapy

Exclusion Criteria:

Metastatic Breast Cancer:

• Patients previously treated with docetaxel (Taxotere) or capecitabine (Xeloda)
• Patients with contraindications for any of study drugs as listed in approved SmPC

Colon Cancer:

• Patients previously treated with chemiotherapy
• Patients with contraindications for study drug as listed in approved SmPC

Patients with early or metastatic colon cancer, and patients with metastatic breast cancer, no age limit